PUBLIC COMPANY
save$ANIPANI PHARMACEUTICALS INC
$ANIP68.55-0.84%Princeton, NJ, USupdated 2h ago
community read0 votes
pipeline
7
marketed
7
phase 3
0
catalysts ytd
6
approvals ytd
2
recalls ytd
0
Pipeline(7)
pipeline depth7 products
7Marketed
Marketed
Chewtadzy
Storage Symptoms of Benign Prostatic Hyperplasia
MarketedCortenema
Proctitis
MarketedREGLAN
Diabetic Gastroparesis
Marketedfluvoxamine maleate
Obsessive-Compulsive Disorder
Marketedlithium carbonate ER
Bipolar Disorder (Manic Depression)
Marketedsinecatechins
Genital Warts (Condylomata Acuminata)
Marketedvancocin hydrochloride
Enterocolitis
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (2)
🐶 Hiring Signal
News
- BioNTech pays $205M for FDA voucher to speed up ‘late-stage oncology pipeline’BioNTech has agreed to pay $205 million to purchase an FDA priority review voucher to support a future filing of a drug in its “late-stage oncology pipeline.” Fierce breaks down which candidate is…fiercebiotech · 9d ago
- Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step downThe deal is part of a course change for Hims, which had previously sold knockoff GLP-1 drugs. Elsewhere, a medicine Servier recently acquired failed a key trial and Ultragenyx announced staff cuts.biopharma_dive · 14d ago
- Rasonque sales drive RevMed's stock; whistleblower sues Madrigal over MASHPlus news about Rezera, ANI Pharmaceuticals, Cloudbreak Pharma and Anaheim Bio. RevMed’s stock jumps on early Rasonque sales: The RAS drug developer reported sales of its pancreatic cancer therapy…endpoints · 15d ago
- Trump threatens tariffs on imported generic drugsWhile the possibility of levies on branded pharmaceuticals have had a limited impact on drugmaker revenues, tariffs of up to 200% on copycat medicines could — depending on the specifics — prove mor…biopharma_dive · 4mo ago
Data sources
last refreshed 26m ago
Found something off?
comments(0)
5-min edit window · permanent after that